Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Link to relevant study record(s)

Description of key information

Metabolites: rapidly metabolised to gamma-hydroxybutyric acid, succinic acid, and carbon dioxide. Dermal Absorption Rate (Estimated): 0.14 mg/cm2-hr.

Key value for chemical safety assessment

Bioaccumulation potential:
no bioaccumulation potential
Absorption rate - oral (%):
100
Absorption rate - dermal (%):
10
Absorption rate - inhalation (%):
10

Additional information

A summary report (NTP, 1996) presents a review of the literature, and NTP-derived data, which documents that 1,4-butanediol (BDO) and γ-butyrolactone (GBL) are both metabolized to γ-hydroxybutyric acid (GHB). The pharmacologic and toxicologic responses to these chemicals are due to this metabolite, or more likely, due to GHB's further metabolism to the neurotransmitter, gamma-aminobutyric acid (GABA). Within 72 hours of oral administration of BDO in rats, approximately 94% was excreted as carbon dioxide in exhaled breath, with appoximately 50% within the first 2 hours. Excretion in urine and feces was approximately 4% and 0.6%, respectively, and the amount remaining in the carcass after 72 hours was 2.28%, with the largest amounts present in liver, muscle, and skin. It has been estimated that approximately 10% of a dose applied percutaneously is absorbed in the rat (Fung, HA, Lettieri, J.T., and Bochner, R. (1979). Percutaneous butyrolactone absorption in rats. J. PharmacoL Sci 68, 1198 -1200).